

688658

悦康药业集团股份有限公司
2021 年年度报告摘要

第一节 重要提示

www.sse.com.cn

□ √

2021 2021 12 31 45,000.00 10 6.80
30,600.00 54,531.60
56.11% 2021

第二节 公司基本情况

A			688658	

()

8 4 2021 2

2022

BD
6

CT102			IIa
	1		I
A	1		III
	1		III
	1		II
	1		II

()

1

2021

mRNA

2022 1 8

2

GMP

1

2

1

2

3

79

GMP

2010

GMP

4

1

1

2

2

()

1.

C27 ”

GB/T4754-2017

2012 10

“

“C ” “

C27 ”

2025

2021

2035

“ ”

1

1

2030

2.1

Frost & Sullivan

2014

1.0

2018

1.3

2030

2.1

GDP

2011

2021

GDP

2020

100

2021

1,143,670

+8.1%

GDP

“

2030”

“

2030

79.0

2020

8

16

”2011

2020

2.43

7.21

CAGR

10.5%

GDP

GDP

2011

5.0%

2020

7.1%

2

2021

5

2020

11

1

60

2.64

18.70%

65

1.90

13.50%

“

”

2030

2020

2015

2020

4.1

7.2

2

1

2018

5

“

”

“

”

“

”

“ ”

2018

“ ”

117

61.71%

94

2021
80.34%

“ ”

2022 1 30 ,

, “ ”

“ ”

+ ”

,

RNA (PROTAC)

,

,

,

(ADC) (HPV) G (GPCR)

T (CAR-T) NK (CAR-NK)

“ ”

2022 3 29 “ ” 2025

10 39 15 “ ”

10 39

15

DRG /DIP

2018 DRG 2019 5 30

“ ” 2020 10

71

2021 1-2

DP

2021 11 26 DRG/DIP

2019-2021 DRG/DIP 2022 2024 DRG/DP

2024 DRG/DIP

2025

DRG/DIP

DRG

/

/

DRG

"

"

"

"

DRG/DIP

2

RNA PROTAC

2021

115.34

37.10% 2021
R&D

69.78

3

1

GMP

GSP

2

3

I III

7 10

2.

1

9 5 2 -

2021 7 2020

3.3 1,300 1,139 890

2.45 60 18.70%

1962-1975 2022 60

17% 2

Frost & Sullivan 2014 1,444 2018

2,060 2023 2,863 2018 2023 6.8%

®

2021

78.42%

--	--	--	--	--	--

2

10%-20%

1.2

700

	H2	

2019

437

2026

60%

1062

(CAGR) 13.4%

		2016	2017	2018	2019
1		18.61%	20.04%	19.36%	18.81%
2		14.83%	14.71%	14.88%	14.65%
3		14.00%	13.78%	14.68%	14.06%

4		6.68%	6.34%	6.44%	7.97%
5		4.89%	4.95%	5.98%	6.37%
		40.99%	40.18%	38.65%	38.15%
		100%	100%	100%	100%

3

IDF

5.78 IDF 2045 2019 7 4.68 2030 1.19
 IDF 2030 1.4

1999

I

1	II	
2	I	
3		
4		

II

II

90%

TZDs

GLP-1

DPP-IV

SGLT-2

Frost &

Sullivan

		HbA1c				
			v			

	GLP-1		×			
		0.7%~1.0%	×			
	a-	0.50%	×		IGT	
		1.0%~1.5%	√			
		0.5%~1.5%	√			
	TZDs	0.7%~1.0%	×			
	DPP-4	0.4%~0.9%	×			
	SGLT2	0.5%~1.0%	×			

-

Frost & Sullivan 600

2020 697 2025

902 2020 2025 5.3% 2030 1,091 2025

2030 3.9% 2020 632

2025 1,161 2020 2025 12.9%

2030 1,675 2025 2030 7.6%

		2016	2017	2018	2019
1		42.91%	42.95%	42.15%	44.10%

2		9.27%	8.20%	10.26%	6.83%
3		7.15%	7.39%	6.95%	6.78%
4		3.08%	3.22%	3.28%	4.04%
5		3.90%	4.02%	3.65%	2.73%
		33.70%	34.22%	33.71%	35.52%
		100%	100%	100%	100%

4

	Frost & Sullivan	2016	2019		2020
	2019	1,662	1,224	2016	2020
		1,535	1,244		-5.1
		1,380	2020	2025	2.1
2024					2025
			2030	1,254	2025
2030		-1.9			

5

		(2013)		erectile dysfunction
ED				3
ED				
			EUA	2015
MMAS		ED	52%	
		40 70		
2226			ED	26.1% 40
	40.2%	2015		
	ED			
		2020		220
			72.3%	23.6%

5%

ED “ ” “863”

“ ”

22

6

RNA mRNA antisense oligonucleotide ASO RNA
 RNAi RNA saRNA RNA mRNA aptamer (ribozyme)
 ARC antisense oligonucleotide ASO RNA
 siRNA small interfering RNA mRNA

	ASO	RNA siRNA	mRNA
	DNA RNA	19-23 RNA	mRNA
	mRNA/miRNA	mRNA	mRNA
	/		
	mRNA miRNA	mRNA	mRNA
	1~3	ASO 3~5 ASO	
	Ionis Sarepta	Alnylam Arrowhead Quark	Moderna CureVac BioNTech

DNA RNA

RNA

DNA

RNA

DNA

mRNA siRNA

mRNA

mRNA 2021 12 14 9 ASO 4

siRNA 1 80% 2015

Evaluate Pharma BCG 2019

19.19 2024 86

2018 2024 35%

BioNTech mRNA Moderna

mRNA Moderna 2021

544.81 Evaluate BCG 2024

86 mRNA

PROTAC mRNA

mRNA ADC

2021

2021 2

1 CT102 "CT102" ASO

2021 9 1.8 mRNA

CMC IND

mRNA CT102

2022 1 4 I 2022 3 24 IIa

2022 1 8

()

,

3.

1

-

2021 11

-

2

			Frost & Sullivan					
			2025	2,954	2020	2025	2020	2025
	CAGR	7.6%;		,2020	2025		CAGR	
15.0%	2025		496	Pharma Projects	2001	2020		
			2001		5,995	2019		17,737
	2001	2.96	2021	4		18,582	2020	
	845				2012	2021	2,465	
		2021	IND		664	2018	2021	
CAGR	47%	2021						76%

21

2021

76

2020

48

26

3

AI

AI

AI+

4-5

AI

1-2

3

2025

80.1

2016 70.9% 2016 2020 73.7% CR4
42.6% CR10 55.2%



3

--	--	--	--	--

	1-3	4-6	7-9	10-12

10

		()			16,831
					14,594
		()			0
					0
					0
					0
			(%)		



10

第三节 重要事项